Introduction {#s0001}
============

Considerable efforts have been focussed in the past decades, on the design and development of new antiproliferative drugs with improved efficiency, limited toxicity, cost-effectiveness, which are synchronously less prone to develop multidrug resistance[@CIT0001]. Among the variety of targets used in this huge anticancer fight, tubulin targeting appears to be a key focus in cancer treatment, the research in this field remaining very active in past years[@CIT0004]. After the success of Colchicine[@CIT0008], combretastatin A-4[@CIT0009], vincristine or vinblastine[@CIT0010] as anticancer drugs acting by inhibiting tubulin polymerisation, research efforts focused on developing new colchicine binding site inhibitors with improved pharmacological profiles[@CIT0004]^,^[@CIT0011].

One of the simplest known structures synthesised and tested as an anticancer agent in the past years is phenstatin[@CIT0012]^,^[@CIT0013] which stand as one of the most potent tubulin polymerisation inhibitors by binding to the colchicine site of the tubulin and thus, interfering with the equilibrium dynamics associated with the cell division[@CIT0014]^,^[@CIT0015]. Because of its biological properties and structural simplicity, phenstatin continues to be a lead compound for rational design in anticancer therapy, the recent literature being plentiful of such phenstatin analogues[@CIT0016].

Pyrrolo-fused derivatives comprise a class of biologically active heterocyclic compounds which can serve as promising scaffolds for the development of anticancer, antimicrobial, antiviral, antimalarial, antitubercular, anti-inflammatory, and enzyme inhibiting drugs[@CIT0019]. Among the fused pyrrolo-heterocyclic compounds, pyrrolo\[1,2-*b*\]pyridazines and its condensed pyrrolo\[2,1-*a*\]phthalazine system are compounds well known for their strong luminescence[@CIT0020]^,^[@CIT0021] and photochromic properties[@CIT0022], and at the same time are promising in the field of drug design[@CIT0023]^,^[@CIT0024], some derivatives being reported to have antimicrobial[@CIT0025]^,^[@CIT0026], antifungal[@CIT0025] or anticancer effects[@CIT0027]^,^[@CIT0028], or to act as acyl CoA:diacylglycerol acyltransferase (DGAT1) inhibitors[@CIT0024], JAK inhibitors[@CIT0029], HER-2 tyrosine kinase inhibitors[@CIT0030], IRAK4 inhibitors[@CIT0031], or MEK inhibitors[@CIT0032].

The replacement of one of the substituted phenyl ring of phenstatin with pyrrolo-fused heterocycles has been a major focus in rational drug design in the recent years, as there are several reported biological active phenstatin analogues containing an indole ring[@CIT0005]^,^[@CIT0019], an indolizine ring[@CIT0033], or a pyrrolo\[2,3-*d*\]pyrimidine ring[@CIT0034]. However, to our knowledge, there are no reported analogues of phenstatin with pyrrolo\[1,2-*b*\]pyridazine or pyrrolo\[2,1-*a*\]phthalazine scaffolds, respectively.

With the aim of exploring new potential antitumour scaffolds, the target compounds described in this paper possess a pyrrolo\[1,2-b\]pyridazin-7-yl or a pyrrolo\[2,1-a\]phthalazin-3-yl moiety in place of the 3′-hydroxy-4′-methoxyphenyl ring of phenstatin. In order to establish structure-activity relationships (SARs), we extended our structural modifications by introducing different substituents at position 2 of the pyrrolo\[1,2-b\]pyridazine unit, including methyl or 4-substituted phenyl rings (4-chlorophenyl, 4-bromophenyl or *p*-tolyl). At the same time, the trimethoxyphenyl ring of phenstatin was replaced either by 3,5-dihydroxyphenyl, 3,4-dimethoxyphenyl or 4-bromophenyl ([Figure 1](#F0001){ref-type="fig"}).

![The structures of phenstatin and the target compounds.](IENZ_A_1550085_F0001_C){#F0001}

Materials and methods {#s0002}
=====================

Chemistry {#s0003}
---------

All commercially available reagents and solvents employed were used without further purification. Melting points were recorded on an A. Krüss Optronic Melting Point Meter KSPI and are uncorrected. Proton and carbon nuclear magnetic resonance (δ~H~, δ~C~) spectra were recorded on a DRX-500 Bruker or a Bruker Avance 400 DRX spectrometers. The following abbreviations were used to designate chemical shift multiplicities: s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet, bs: broad singlet, as: apparent singlet. All chemical shifts are quoted on the δ-scale in ppm. Coupling constants are given in Hz. IR spectra were recorded on a FTIR Shimadzu or Jasco 660 plus FTIR spectrophotometer. Analyses indicated by the symbols of the elements or functions were within ±0.4% of the theoretical values. Thin layer chromatography (TLC) was carried out on Merck silica gel 60F~254~ plates. Visualisation of the plates was achieved using a UV lamp (λ~max~ = 254 or 365 nm).

Compounds 7d, 7h, 7l, 8d, 10a, and 10d were previously reported[@CIT0035].

### General procedure for the synthesis of monoquaternary salts 7 and 10 {#s0004}

1 mmol of heterocycle (pyridazine **1**, 3-methylpyridazine **2**, 3--(4-chlorophenyl)pyridazine) **3**, 3--(4-bromophenyl)pyridazine **4**, 3-(*p*-tolyl)pyridazine **5** or phthalazine **9** was dissolved in 7 ml acetone (for compounds **1--5**) or acetonitrile for compound **9**. Then 1.1 mmol of reactive halide (2-bromo-1--(3,4,5-trimethoxyphenyl)ethanone **6a**, 2-bromo-1--(3,5-dimethoxyphenyl) ethanone **6 b**, 2-bromo-1--(3,4-dimethoxyphenyl) ethanone **6c** or 2-bromo-1--(4-bromophenyl) ethanone **6d**) was added and the resulted mixture was stirred overnight at room temperature (to obtain compounds **7**) or reflux (for synthesis of compounds **10**). The reaction mixture was cooled and the formed precipitate was filtered and washed with diethyl ether to give the desired product which was used in the next reaction without any further purification. In case of salts **7e--g**, the resulting salts have not crystallised; for these compounds, the solvent was removed under vacuum, and the resulting liquid was used in the next step.

### General procedure for preparation of compounds 8a--t and 11a--d {#s0005}

The cycloimmonium salt (**7a--d** or **10a--d)** (1 mmol) and ethyl propiolate (1.1 mmol) were added to 10 ml of anhydrous acetone and the obtained suspension was stirred at room temperature. Then, a solution of triethylamine (TEA) (3 mmol, 3 equiv.) in anhydrous acetone (3 ml) was added drop-wise over 1 h (magnetic stirring) and the resulting mixture was then stirred overnight at room temperature. Water (10 ml) was added and the formed solid was collected by filtration to give a powder which was washed with 5 ml methanol. The product was crystallised from dichloromethane/methanol (1:1, v/v).

*1--(2-Oxo-2--(3,4,5-trimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7a***. Beige powder, Yield: 61%; m.p. 152--153 °C; IR (KBr, cm^−1^): 1672, 1583, 1416, 1319, 1165, 1128. ^1^H NMR (500 MHz DMSO-d~6~) *δ* 3.80 (s, 3H, OMe), 3.90 (s, 6H, 2 × OMe), 6.82 (s, 2H, H7), 7.39 (s, 2H, H10, H14), 8.76 (t, *J* =  6.0 Hz, 1H, H4), 8.90 (t, *J* =  6.0 Hz, 1H, H5), 9.74 (d, *J* =  3.5 Hz, 1H, H3), 9.74 (d, *J* =  5.0 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 56.4 (2 × OMe), 60.4 (OMe), 70.3 (C7), 106.2 (C10, C14), 136.0 (C5), 137.5 (C4), 143.3 (C12), 151.9 (C6), 153.1 (C11, C13), 154.7 (C3), 189.3 (C8). Anal. calcd. for C~15~H~17~BrN~2~O~4~: C, 48.80; H, 4.64; N, 7.59%. Found: C, 48.79; H, 4.55; N, 7.62%.

*1--(2-Oxo-2--(3,5-dimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7b***. Beige powder, Yield: 60%; m.p. 196--199 °C; IR (KBr, cm^−1^): 1684, 1586, 1438, 1334, 1209, 1157, 1058. ^1^H NMR (500 MHz DMSO-d~6~): *δ* 3.85 (s, 6H, 2 × OMe), 6.76 (s, 2H, H7), 6.94 (t, *J* =  2.0 Hz, 1H, H12), 7.21 (d, *J* =  2.5 Hz, 2H, H10, H14), 8.75 (dd, *J* =  8.0; 4.5 Hz, 1H, H4), 8.88 (m, 1H, H5), 9.74 (d, *J* =  5.5 Hz, 1H, H3), 9.90 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~): *δ* 55.8 (2 × OMe), 70.4 (C7), 106.3 (C10, C14), 106.5 (C12), 135.2 (C9), 136.0 (C5), 137.6 (C4), 151.9 (C6), 154.7 (C3), 160.9 (C11, C13), 190.2 (C8). Anal. calcd. for C~14~H~15~BrN~2~O~3~: C, 49.57; H, 4.46; N, 8.26%. Found: C, 49.59; H, 4.42; N, 8.32%.

*1--(2-Oxo-2--(3,4-dimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7c***. Beige solid, Yield: 60%; m.p. 123--124 °C; IR (KBr, cm^−1^): 2979, 1677, 1586, 1518, 1294, 1205, 1168. ^1^H NMR (500 MHz DMSO-d~6~): δ 3.85 (s, 3H, OMe), 3.90 (s, 3H, OMe), 6.79 (s, 2H, H7), 7.22 (d, *J* =  8.5 Hz, 1H, H13), 7.53 (d, *J* =  2.0 Hz, 1H, H10), 7.81 (dd, *J* =  8.5; 2.0 Hz, 1H, H14), 8.77 (m, 1H, H4), 8.91 (m, 1H, H5), 9.75 (dd, *J* =  5.0; 1.0 Hz, 1H, H3), 9.97 (d, *J* =  6.0 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~): *δ* 55.8 (OMe), 56.1 (OMe), 70.1 (C7), 110.4 (C10), 111.3 (C14), 123.7 (C13), 126.0 (C9), 136.0 (C5), 137.5 (C4), 151.9 (C6), 154.7 (C3), 148.9 (C11), 154.5 (C12), 188.7 (C8). Anal. calcd. for C~14~H~15~BrN~2~O~3~: C, 49.57; H, 4.46; N, 8.26%. Found: C, 49.55; H, 4.44; N, 8.30%.

*1--(2-Oxo-2--(4-bromophenyl)ethyl)pyridazin-1-ium bromide****7d***. White solid, Yield: 66%; m.p. 235--237 °C; IR (KBr, cm^−1^): 3017, 2976, 1695, 1580, 1439, 1394, 1229, 976, 822. ^1^H NMR (400 MHz DMSO-d~6~): δ 6.75 (s, 2H, H7), 7.90 (d, *J* =  8.4 Hz, 2H, H11, H13), 8.03 (d, *J* =  8.4 Hz, 2H, H10, H14), 8.78 (m, 1H, H4), 8.92 (m, 1H, H5), 9.76 (dd, *J* =  6.0; 0.8 Hz, 1H, H3), 9.99 (d, *J* =  6.0 Hz, 1H, H6). ^13 ^C NMR (100 MHz DMSO-d~6~): *δ* 70.2 (C7), 129.1 (C12), 130.4 (C10, C14), 132.2 (C11, C13), 135.4 (C9), 136.0 (C5), 137.5 (C4), 151.8 (C6), 154.7 (C3), 189.8 (C8). Anal. calcd. for C~12~H~10~Br~2~N~2~O: C, 40.26; H, 2.82; N, 7.82%. Found: C, 40.25; H, 2.79; N, 7.84%.

*3-Methyl-1--(2-oxo-2--(3,4,5-trimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7e***. Liquid, Yield: 50%; IR (cm^−1^): 3069, 2943, 1687, 1586, 1417, 1332, 1126, 1050, 921. ^1^H NMR (500 MHz DMSO-d~6~) δ 2.81 (s, 3H, Me), 3.80 (s, 3H, OMe), 3.89 (s, 6H, 2 × OMe), 6.76 (s, 2H, H7), 7.38 (s, 2H, H10, H14), 8.65 (d, *J* =  8.5 Hz, 1H, H4), 8.77 (dd, *J* =  8.5; 6.0 Hz, 1H, H5), 9.80 (d, *J* =  6.0 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~): *δ* 21.6 (Me), 56.4 (2 × OMe), 60.4 (OMe), 70.1 (C7), 106.2 (C10, C14), 128.5 (C9), 135.0 (C5), 138.4 (C4), 143.3 (C12), 149.7 (C6), 153.1 (2 x C11), 164.9 (C3), 189.3 (C8).

*3-Methyl-1--(2-oxo-2--(3,5-dimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7f***. Liquid, Yield: 50%; IR (cm^−1^): 3069, 2943, 1687, 1586, 1417, 1332, 1164, 1050, 921. ^1^H NMR (500 MHz DMSO-d~6~): δ 2.90 (s, 3H, Me), 3.84 (s, 6H, 2 × OMe), 6.63 (s, 2H, H7), 6.90 (t, *J* =  2.0 Hz, 1H, H12), 7.20 (d, *J* =  2.5 Hz, 2H, H10, H14), 8.67 (d, *J* =  8.5 Hz, 1H, H4), 8.78 (dd, *J* =  8.5; 5.5 Hz, 1H, H5), 9.87 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 21.6 (Me), 55.9 (2 × OMe), 70.3 (C7), 106.3 (C10, C14), 106.6 (C12); 135.0 (C9), 135.2 (C5), 138.4 (C4), 149.6 (C6), 160.8 (C11, C13), 164.8 (C3), 190.2 (C8).

*3-Methyl-1--(2-oxo-2--(3,4-dimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7g***. Liquid; Yield: 51%; IR (cm^−1^): 2969, 1682, 1586, 1517, 1270, 1019, 806. ^1^H NMR (DMSO-d~6~, 500 MHz) δ 2.80 (s, 3H, Me), 3.84 (s, 3H, OMe), 3.84 (s, 3H, OMe), 6.78 (s, 2H, H7), 7.18 (d, *J* =  8.5 Hz, 1H, H12), 7.51 (d, *J* =  2.0 Hz, 1H, H10), 7.79 (dd, *J* =  8.5; 2.0 Hz, 1H, H14), 8.68 (1H, d, *J* =  8.5 Hz, H4), 8.80 (1H, dd, *J* =  8.5; 5.5 Hz, H5), 9.93 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~): *δ* = 21.7 (Me), 55.8 (OMe), 56.0 (OMe), 70.0 (C~7~), 110.5 (C~10~), 111.4 (C~14~), 123.8 (C~13~), 126.1 (C~9~), 135.0 (C~5~), 138.3 (C~4~), 149.7 (C~6~), 148.9 (C~11~), 154.5 (C~12~), 164.8 (C~3~), 188.7 (C~8~).

*3-Methyl-1--(2-oxo-2--(4-bromophenyl)ethyl)pyridazin-1-ium bromide****7h***. Beige solid, Yield: 70%; m.p. 216--218 °C; IR (KBr, cm^−1^): 3013, 2976, 1692, 1586, 1468, 1231, 1072, 988, 828. ^1^H NMR (500 MHz DMSO-d~6~) δ 2.81 (s, 3H, Me), 6.74 (s, 2H, H7), 7.89 (d, *J* =  8.5 Hz, 2H, H11, H13), 8.02 (d, *J* =  8.5 Hz, 2H, H10, H14), 8.66 (d, *J* =  8.5 Hz, 1H, H4), 8.78 (dd, *J* =  8.5; 6.0 Hz, 1H, H5), 9.82 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 21.6 (Me), 70.0 (C7), 129.1 (C12); 130.4 (C10, C14), 132.3 (C11, C13), 132.4 (C9), 135.0 (C5), 138.4 (C4), 149.7 (C6), 164.8 (C3), 189.8 (C8). Anal. calcd. for C~13~H~12~Br~2~N~2~O: C, 41.97; H, 3.25; N, 7.53%. Found: C, 42.00; H, 3.18; N, 7.55%.

*3--(4-Chlorophenyl)-1--(2-oxo-2--(3,4,5-trimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7i***. Beige **s**olid, Yield 74%; m.p. 186--188 °C; IR (KBr, cm^−1^): 3059, 2932, 1682, 1599, 1450, 1343, 1132. ^1^H NMR (500 MHz DMSO-d~6~) δ 3.81 (s, 3H, OMe), 3.90 (s, 6H, 2 × OMe), 6.91 (s, 2H, H7), 7.42 (s, 2H, H10, H14), 7.76 (d, *J* =  7.5 Hz, 2H, H17, H19), 8.25 (d, *J* =  8.0 Hz, 2H, H16, H20), 8.96 (dd, *J* =  9.0; 4.5 Hz, 1H, H5), 9.33 (d, *J* =  9.0 Hz, 1H, H4), 9.93 (d, *J* =  4.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 56.3 (2 × OMe), 60.3 (OMe), 70.5 (C7), 106.2 (C10, C14), 128.4 (C9), 129.6 (C16, C20, C17, C19), 130.5 (C15), 134.7 (C4), 136.3 (C5), 137.7 (C18), 143.2 (C12), 150.0 (C6), 153.0 (C11, C13), 159.9 (C3), 189.1 (C8). Anal. calcd. for C~21~H~20~BrClN~2~O~4~: C, 52.57; H, 4.20; N, 5.84%. Found: C, 52.55; H, 4.18; N, 5.87%.

*3--(4-Chlorophenyl)-1--(2-oxo-2--(3,5-dimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7j***. Beige solid, Yield: 75%; m.p. 220--222 °C; IR (KBr, cm^−1^): 3034, 2980, 1697, 1599, 1456, 1356, 1204, 1153, 841. ^1^H NMR (500 MHz DMSO-d~6~) δ 3.86 (s, 6H, 2 × OMe), 6.83 (s, 2H, H7), 6.95 (as, 1H, H12), 7.24 (as, 2H, H10, H14), 7.77 (d, *J* =  8.5 Hz, 2H, H17, H19), 8.25 (d, *J* =  8.5 Hz, 2H, H16, H20), 8.95 (dd, *J* =  9.0; 5.5 Hz, 1H, H5), 9.31 (d, *J* =  9.0 Hz, 1H, H4), 9.87 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 55.8 (2 × OMe), 70.7 (C7), 106.3 (C10, C14), 106.6 (C12); 129.7 (C16, C20), 129.8 (C17, C19), 130.6 (C15), 134.8 (C4), 135.2 (C9), 136.4 (C5), 137.8 (C18), 150.1 (C6), 160.2 (C3), 160.9 (C11, C13); 190.0 (C8). Anal. calcd. for C~20~H~18~BrClN~2~O~3~: C, 53.41; H, 4.03; N, 6.23%. Found: C, 53.45; H, 4.00; N, 6.27%.

*3--(4-Chlorophenyl)-1--(2-oxo-2--(3,4-dimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7k***. Beige solid, Yield 77%; m.p. 144--146 °C; IR (KBr, cm^−1^): 3055, 2936, 1680, 1597, 1518, 1452, 1333, 1271, 1157, 1092, 1015. ^1^H NMR (500 MHz DMSO-d~6~) δ 3.86 (s, 3H, OMe), 3.91 (s, 3H, OMe), 6.79 (s, 2H, H7), 7.23 (d, *J* =  8.0 Hz, 1H, H13), 7.55 (s, 1H, H10), 7.76 (d, *J* =  7.5 Hz, 2H, H17, H19), 7.82 (d, *J* =  8.0 Hz, 1H, H14), 8.24 (d, *J* =  7.5 Hz, 2H, H16, H20), 8.94 (dd, *J* =  8.5; 5.5 Hz, 1H, H5), 9.30 (d, *J* =  8.5 Hz, 1H, H4), 9.87 (d, *J* =  4.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 55.8 (OMe), 56.0 (OMe), 70.3 (C7), 110.5 (C10), 111.3 (C13), 123.7 (C14), 126.0 (C9), 129.7 (C16, C20, C17, C19), 130.6 (C15), 134.7 (C4), 136.3 (C5), 137.8 (C18), 148.9 (C11), 150.1 (C6), 154.6 (C12); 160.1 (C3), 188.4 (C8). Anal. calcd. for C~20~H~18~BrClN~2~O~3~: C, 53.41; H, 4.03; N, 6.23%. Found: C, 53.44; H, 3.99; N, 6.27%.

*3--(4-Chlorophenyl)-1--(2-oxo-2--(4-bromophenyl)ethyl)pyridazin-1-ium bromide****7l***. Yellow solid, Yield: 75%; m.p. 200--202 °C; IR (KBr, cm^−1^): 3055, 2992, 1690, 1587, 1447, 1395, 1333, 1233, 1096, 986, 824. ^1^H NMR (500 MHz DMSO-d~6~) δ 6.86 (s, 2H, H7), 7.76 (d, *J* =  6.5 Hz, 2H, H17, H19), 7.90 (d, *J* =  6.0 Hz, 2H, H11, H13), 8.04 (d, *J* =  6.0 Hz, 2H, H10, H14), 8.25 (d, *J* =  6.5 Hz, 2H, H16, H20), 8.96 (bs, 1H, H5), 9.33 (d, *J* =  7.5 Hz, 1H, H4), 9.93 (bs, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 70.5 (C7), 129.2 (C12), 129.7 (C16, C20), 129.8 (C17, C19), 130.4 (C11, C13), 130.6 (C15), 132.3 (C10, C14), 132.4 (C9), 134.8 (C4), 136.4 (C5), 137.8 (C18), 150.1 (C6), 160.1 (C3), 189.7 (C8). Anal. calcd. for C~18~H~13~Br~2~ClN~2~O: C, 46.14; H, 2.80; N, 5.98%. Found: C, 46.14; H, 2.77; N, 6.01%.

*3--(4-Bromophenyl)-1--(2-oxo-2--(3,4,5-trimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7m***. Brown solid, Yield: 75%; m.p. 185--187 °C; IR (KBr, cm^−1^): 2930, 1680, 1585, 1456, 1340, 1132. ^1^H NMR (500 MHz DMSO-d~6~) δ 3.82 (s, 3H, OMe), 3.92 (s, 6H, 2 × OMe), 6.90 (s, 2H, H7), 7.43 (s, 2H, H10, H14), 7.91 (d, *J* =  8.0 Hz, 2H, H17, H19), 8.18 (d, *J* =  8.0 Hz, 2H, H16, H20), 8.97 (dd, *J* =  9.0; 4.5 Hz, 1H, H5), 9.33 (d, *J* =  9.0 Hz, 1H, H4), 9.92 (d, *J* =  4.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 56.4 (2 × OMe), 60.4 (OMe), 70.6 (C7), 106.2 (C10, C14), 126.8 (C18), 128.5 (C9), 129.9 (C16, C20), 130.9 (C15), 132.6 (C17, C19), 134.7 (C4), 136.4 (C5), 143.3 (C12), 150.1 (C6), 153.0 (C11, C13), 160.3 (C3), 189.2 (C8). Anal. calcd. for C~21~H~20~Br~2~N~2~O~4~: C, 48.12; H, 3.85; N, 5.34%. Found: C, 48.15; H, 3.79; N, 5.37%.

*3--(4-Bromophenyl)-1--(2-oxo-2--(3,5-dimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7n***. Brown solid, Yield: 73%; m.p. 217--220 °C; IR (KBr, cm^−1^): 3078, 2926, 1695, 1591, 1452, 1385, 1103, 1074. ^1^H NMR (500 MHz DMSO-d~6~) δ 3.85 (s, 6H, 2 × OMe), 6.82 (s, 2H, H7), 7.23 (s, 2H, H10, H14), 7.91 (d, *J* =  8.0 Hz, 2H, H17, H19), 8.17 (d, *J* =  8.0 Hz, 2H, H16, H20), 8.95 (dd, *J* =  9.0; 4.5 Hz, 1H, H5), 9.30 (d, *J* =  9.0 Hz, 1H, H4), 9.86 (d, *J* =  4.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 56.7 (2 × OMe), 70.7 (C7), 106.6 (C12), 107.1 (C10, C14), 127.7 (C18), 128.9 (C16, C20), 130.8 (C15), 132.7 (C17, C19), 134.8 (C4), 135.2 (C9), 136.3 (C5), 150.8 (C6), 160.3 (C3), 160.9 (C11, C13), 189.9 (C8). Anal. calcd. for C~20~H~18~Br~2~N~2~O~3~: C, 48.61; H, 3.67; N, 5.67%. Found: C, 48.65; H, 3.66; N, 5.67%.

*3--(4-Bromophenyl)-1--(2-oxo-2--(3,4-dimethoxyphenyl)ethyl)pyridazin-1-ium bromide****7o***. Brown solid, Yield: 72%; m.p. 210--212 °C; IR (KBr, cm^−1^): 3049, 2975, 1697, 1596, 1453, 1358, 1261, 1207. ^1^H NMR (500 MHz DMSO-d~6~) δ 3.86 (s, 3H, 2 OMe), 3.91 (s, 3H, 2 OMe), 6.80 (s, 2H, H7), 7.23 (d, *J* =  8.5 Hz, 1H, H13), 7.55 (d, *J* =  2.0 Hz, 1H, H10), 7.83 (dd, *J* =  8.5; 2.0 Hz, 1H, H14), 7.91 (d, *J* =  8.5 Hz, 2H, H17, H19), 8.17 (d, *J* =  8.5 Hz, 2H, H16, H20), 8.95 (dd, *J* =  9.0; 5.5 Hz, 1H, H5), 9.31 (d, *J* =  9.0 Hz, 1H, H4), 9.87 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 55.8 (OMe), 56.1 (OMe), 70.4 (C7), 110.4 (C10), 111.3 (C13), 123.7 (C14), 126.0 (C9), 126.9 (C18), 129.9 (C16, C20), 131.0 (C15), 132.7 (C17, C19), 134.7 (C4), 136.4 (C5), 148.9 (C11), 150.1 (C6), 154.6 (C12); 160.3 (C3), 188.5 (C8). Anal. calcd. for C~20~H~18~Br~2~N~2~O~3~: C, 48.61; H, 3.67; N, 5.67%. Found: C, 48.62; H, 3.64; N, 5.68%.

*3--(4-Bromophenyl)-1--(2-oxo-2--(4-bromophenyl)ethyl)pyridazin-1-ium bromide****7p***. Brown solid, Yield: 80%; m.p. 206--208 °C; IR (KBr, cm^−1^): 3055, 1690, 1587, 1447, 1387, 1333, 1233, 1076, 986, 827. ^1^H NMR (500 MHz DMSO-d~6~) δ 6.84 (s, 2H, H7), 7.90 (d, *J* =  8.5 Hz, 2H, H11, H13), 7.91 (d, *J* =  8.0 Hz, 2H, H17, H19), 8.04 (d, *J* =  8.0 Hz, 2H, H16, H20), 8.17 (d, *J* =  8.5 Hz, 2H, H10, H14), 8.95 (dd, *J* =  8.0; 5.5 Hz, 1H, H5), 9.32 (d, *J* =  8.0 Hz, 1H, H4), 9.89 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 70.5 (C7), 126.9 (C18), 129.2 (C12), 129.9 (C10, C14), 130.4 (C16, C20), 131.0 (C15), 132.2 (C11, C13), 132.4 (C9), 132.6 (C17, C19), 134.8 (C4), 136.4 (C5), 150.1 (C6), 160.3 (C3), 189.6 (C8). Anal. calcd. for C~18~H~13~Br~3~N~2~O: C, 42.14; H, 2.55; N, 5.46%. Found: C, 42.12; H, 2.54; N, 5.48%.

*1--(2-Oxo-2--(3,4,5-trimethoxyphenyl)ethyl)-3-(p-tolyl)pyridazin-1-ium bromide****7q***. Beige solid, Yield: 78%; m.p. 208--210 °C; IR (KBr, cm^−1^): 3040, 2990, 2928, 1688, 1587, 1454, 1343, 1132, 990. ^1^H NMR (500 MHz DMSO-d~6~) δ 2.43 (s, 3H, Me), 3.81 (s, 3H, OMe), 3.91 (s, 6H, 2 × OMe), 6.87 (s, 2H, H7), 7.42 (s, 2H, H10, H14), 7.48 (d, *J* =  8.0 Hz, 2H, H17, H19), 8.13 (d, *J* =  8.0 Hz, 2H, H16, H20), 8.92 (dd, *J* =  9.0; 5.5 Hz, 1H, H5), 9.28 (d, *J* =  9.0 Hz, 1H, H4), 9.86 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 21.1 (Me), 56.4 (2 × OMe), 60.4 (OMe), 70.6 (C7), 106.2 (C10, C14), 127.8 (C16, C20), 128.5 (C9), 128.9 (C15), 130.2 (C17, C19), 134.3 (C4), 136.2 (C5), 143.2 (C18), 143.3 (C12), 149.6 (C6), 153.1 (C11, C13), 161.1 (C3), 189.3 (C8). Anal. calcd. for C~22~H~23~BrN~2~O~4~: C, 57.53; H, 5.05; N, 6.10%. Found: C, 57.55; H, 5.01; N, 6.13%.

*1--(2-Oxo-2--(3,5-dimethoxyphenyl)ethyl)-3-(p-tolyl)pyridazin-1-ium bromide****7r***. Beige solid, Yield: 75%; m.p. 180--182 °C; IR (KBr, cm^−1^): 3042, 2974, 1695, 1591, 1456, 1202, 1155, 808. ^1^H NMR (500 MHz DMSO-d~6~) δ 2.43 (s, 3H, Me), 3.86 (s, 6H, 2 × OMe), 6.82 (s, 2H, H7), 6.94 (t, *J* =  2.5 Hz, 1H, H12), 7.24 (d, J = 2.5 Hz, 2H, H10, H14), 7.48 (d, *J* =  8.5 Hz, 2H, H17, H19), 8.13 (d, *J* =  8.5 Hz, 2H, H16, H20), 8.90 (dd, *J* =  9.0; 5.5 Hz, 1H, H5), 9.27 (d, *J* =  9.0 Hz, 1H, H4), 9.84 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 21.1 (Me), 55.8 (2 × OMe), 70.7 (C7), 106.3 (C10, C14), 106.6 (C12); 127.8 (C16, C20), 128.9 (C15), 130.2 (C17, C19), 134.3 (C4), 135.2 (C9), 136.1 (C5), 143.2 (C18), 149.6 (C6), 160.9 (C11, C13); 161.1 (C3), 190.1 (C8). Anal. calcd. for C~21~H~21~BrN~2~O~3~: C, 58.75; H, 4.93; N, 6.53%. Found: C, 58.77; H, 4.89; N, 6.55%.

*1--(2-Oxo-2--(3,4-dimethoxyphenyl)ethyl)-3-(p-tolyl)pyridazin-1-ium bromide****7s***. Beige solid, Yield: 75%; m.p. 150--151 °C; IR (KBr, cm^−1^): 3009, 2962, 1679, 1590, 1518, 1455, 1268, 1160, 1024. ^1^H NMR (500 MHz DMSO-d~6~) δ 2.42 (s, 3H, Me), 3.86 (s, 3H, OMe), 3.91 (s, 3H, OMe), 6.79 (s, 2H, H7), 6.94 (d, *J* =  8.5 Hz, 1H, H13), 7.55 (d, *J* =  1.5 Hz, 2H, H10), 7.48 (d, *J* =  8.0 Hz, 2H, H17, H19), 7.83 (dd, *J* =  8.5; 1.5 Hz, 1H, H14), 8.13 (d, *J* =  8.0 Hz, 2H, H16, H20), 8.90 (dd, *J* =  8.5; 5.5 Hz, 1H, H5), 9.27 (d, *J* =  9.0 Hz, 1H, H4), 9.83 (d, *J* =  5.5 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 21.1 (Me), 55.8 (OMe), 56.1 (OMe), 70.3 (C7), 110.4 (C10), 111.3 (C13); 123.7 (C14), 126.1 (C9), 127.9 (C16, C20), 128.9 (C15), 130.3 (C17, C19), 134.3 (C4), 136.1 (C5), 143.3 (C18), 148.9 (C11), 149.7 (C6), 154.5 (C12), 161.1 (C3), 188.6 (C8). Anal. calcd. for C~21~H~21~BrN~2~O~3~: C, 58.75; H, 4.93; N, 6.53%. Found: C, 58.78; H, 4.90; N, 6.56%.

*1--(2-Oxo-2--(4-bromophenyl)ethyl)-3-(p-tolyl)pyridazin-1-ium bromide****7t***. Yellow solid, Yield: 77%; m.p. 208--210 °C; IR (KBr, cm^−1^): 3022, 2988, 1694, 1584, 1452, 1219, 984. ^1^H NMR (500 MHz DMSO-d~6~) δ 2.42 (s, 3H, Me), 6.84 (s, 2H, H7), 7.47 (d, *J* =  8.0 Hz, 2H, H11, H13), 7.91 (d, *J* =  8.5 Hz, 2H, H17, H19), 8.05 (d, *J* =  8.5 Hz, 2H, H16, H20), 8.13 (d, *J* =  8.0 Hz, 2H, H10, H14), 8.91 (dd, *J* =  9.0; 6.0 Hz, 1H, H5), 9.28 (d, *J* =  9.0 Hz, 1H, H4), 9.86 (d, *J* =  6.0 Hz, 1H, H6). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 21.1 (Me), 70.5 (C7), 127.9 (C16, C20), 128.9 (C15), 129.2 (C12), 130.2 (C17, C19), 130.4 (C11, C13), 132.3 (C10, C14), 132.5 (C9), 134.3 (C4), 136.1 (C5), 143.2 (C18), 149.7 (C6), 161.0 (C3), 189.7 (C8). Anal. calcd. for C~19~H~16~Br~2~N~2~O: C, 50.92; H, 3.60; N, 6.25%. Found: C, 50.93; H, 3.56; N, 6.26%.

*Ethyl 7--(3,4,5-trimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8a***. Beige powder, Yield: 55%; m.p. 188--190 °C; IR (KBr, cm^−1^): 1703, 1635, 1584, 1474, 1323, 1217, 1128, 1051; ^1^H NMR (500 MHz CDCl~3~) δ 1.41 (t, *J* =  7.0 Hz, 3H, CH3), 3.90 (s, 6H, 2 × OMe), 3.96 (s, 3H, OMe), 4.40 (q, *J* =  7.0 Hz, 2H, CH2), 7.15 (dd, *J* =  9.0; 4.5 Hz, 1H, H3), 7.17 (s, 2H, H12, H16), 7.77 (s, 1H, H6), 8.53 (as, 1H, H4), 8.67 (d, *J* =  9.0 Hz, 1H,H2). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 55.5 (2 × OMe), 60.6 (CH~2~), 61.2 (OMe), 105.5 (C5), 107.4 (C12, C16), 117.6 (C3), 124.4 (C6), 126.8 (C7), 128.2 (C2), 133.5 (C8), 134.2 (C14), 142.2 (C11), 144.3 (C4), 153.2 (C13, C15), 163.7 (COO), 183.6 (C10). Anal. calcd. for C~20~H~20~N~2~O~6~: C, 62.49; H, 5.24; N, 7.29%. Found: C, 64.59; H, 5.15; N, 7.32%.

*Ethyl 7--(3,5-dimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8b***. Yellow powder, Yield: 57%; m.p. 178--180 °C; IR (KBr, cm^−1^): 1685, 1631, 1587, 1479, 1358, 1225, 1047 (C-O); ^1^H NMR (500 MHz CDCl~3~) δ 1.40 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.85 (s, 6H, 2 × OMe), 4.39 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.68 (s, 1H, H14), 7.01 (d, *J* =  1.5 Hz, 2H, H12, H16), 7.15 (dd, *J* =  9.5; 4.5 Hz, 1H, H3), 7.78 (s, 1H, H6), 8.54 (d, *J* =  3.0 Hz, 1H, H4), 8.67 (d, *J* =  9.0 Hz, 1H, H2). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.6 (CH~3~), 55.8 (2 × OMe), 60.6 (CH~2~), 104.7 (C14), 105.5 (C5), 107.6 (C12, C16), 117.8 (C3), 125.2 (C6), 126.7 (C7), 128.2 (C2), 133.7 (C8), 141.1 (C11), 144.4 (C4), 160.8 (C13, C15), 163.7 (COO), 184.1 (C10). Anal. calcd. for C~19~H~18~N~2~O~5~: C, 64.40; H, 5.12; N, 7.91%. Found: C, 64.52; H, 5.05; N, 7.99%.

*Ethyl 7--(3,4-dimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8c***. Beige solid, Yield: 50%; m.p. 123--124 °C; IR (KBr, cm^−1^): 1704, 1629, 1580, 1371, 1132, 1023; ^1^H NMR (500 MHz CDCl~3~) δ 1.41 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.96 (s, 3H, OMe), 3.98 (s, 3H, OMe), 4.39 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.95 (d, 1H, *J* =  8.0 Hz, H15), 7.12 (dd, *J* =  9.5; 4.5 Hz, 1H, H3), 7.55 (d, *J* =  1.5 Hz, 1H, H12), 7.56 (dd, *J* =  8.0; 1.5 Hz, 1H, H16), 7.75 (s, 1H, H6), 8.50 (dd, *J* =  4.0; 2.0 Hz, 1H, H4), 8.65 (dd, *J* =  9.0; 2.0 Hz, 1H, H2). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 56.2 (OMe), 56.3 (OMe), 60.5 (CH~2~), 105.2 (C5), 110.1 (C12), 112.0 (C15), 117.3 (C3), 123.9 (C16), 124.8 (C6), 126.9 (C7), 128.2 (C2), 131.7 (C11), 133.2 (C8), 144.2 (C4), 149.2 (C13), 153.2 (C14), 163.8 (COO), 184.4 (C10). Anal. calcd. for C~19~H~18~N~2~O~5~: C, 64.40; H, 5.12; N, 7.91%. Found: C, 64.44; H, 5.07; N, 7.97%.

*Ethyl 7--(4-bromobenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8d***. Yellow solid, Yield: 57%; m.p. 133--135 °C; IR (KBr, cm^−1^): 1707, 1638, 1468, 1235, 1190, 1096; ^1^H NMR (500 MHz CDCl~3~) δ 1.40 (t, *J* =  7.0 Hz, 3H, CH~3~), 4.38 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.17 (dd, *J* =  9.0; 4.5 Hz, 1H, H3), 7.65 (d, *J* =  8.0 Hz, 2H, H13, H15), 7.72 (s, 1H, H6), 7.77 (d, *J* =  8.0 Hz, 2H, H12, H16), 8.54 (dd, *J* =  4.0; 1.5 Hz, 1H, H4), 8.67 (dd, *J* =  9.5; 4.0 Hz, 1H, H2). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.6 (CH~3~), 60.7 (CH~2~), 105.7 (C5), 118.0 (C3), 125.0 (C6), 126.4 (C7), 127.4 (C14), 128.2 (C2), 131.2 (C12, C16), 131.9 (C13, C15), 133.8 (C8), 137.9 (C11), 144.5 (C4), 163.6 (COO), 183.3 (C10). Anal. calcd. for C~17~H~13~BrN~2~O~3~: C, 54.71; H, 3.51; N, 7.51%. Found: C, 54.74; H, 3.47; N, 7.57%.

*Ethyl 2-methyl-7--(3,4,5-trimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8e***. Beige solid; Yield: 47%; m.p. 91--93 °C; IR (KBr, cm^−1^): 2978,1695, 1656, 1586, 1470, 1368, 1233, 1124, 754; ^1^H NMR (500 MHz CDCl~3~) δ 1.40 (t, *J* =  7.0 Hz, 3H, CH~3~), 2.64 (s, 3H,Me), 3.90 (s, 6H, 2 × OMe), 3.95 (s, 3H, OMe), 4.38 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.02 (d, *J* =  9.0 Hz, 1H, H3), 7.18 (s, 2H, H12, H16), 7.68 (s, 1H, H6), 8.52 (d, *J* =  9.0 Hz, 1H, H4). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 22.4 (Me), 56.5 (2 × OMe), 60.5 (CH~2~), 61.2 (OMe), 105.1 (C5), 107.5 (C12, C16), 119.7 (C3), 123.8 (C6), 126.6 (C7), 127.6 (C11), 132.3 (C8), 134.3 (C14), 142.2 (C4), 153.1 (C13, C15), 153.4 (C2), 163.9 (COO), 183.5 (C10). Anal. calcd. for C~21~H~22~N~2~O~6~: C, 63.31; H, 5.57; N, 7.03%. Found: C, 63.29; H, 5.55; N, 7.00%.

*Ethyl 2-methyl-7--(3,5-dimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8f***. Beige solid, Yield: 45%; m.p. 96--98 °C; IR (KBr, cm^−1^): 2937, 1681, 1654, 1592, 1436, 1361, 1232, 1158, 754; ^1^H NMR (500 MHz CDCl~3~) δ 1.39 (t, *J* =  7.0 Hz, 3H, CH~3~), 2.65 (s, 3H,Me), 3.84 (s, 6H, 2 × OMe), 4.37 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.68 (s, 1H, H14), 7.02 (overlapped signals, 3H, H3, H12, H16), 7.69 (s, 1H, H6), 8.52 (d, *J* =  9.5 Hz, 1H, H4). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.6 (CH~3~), 22.4 (Me), 55.8 (2 × OMe), 60.5 (CH~2~), 104.6 (C14), 105.2 (C5), 107.6 (C12, C16), 119.9 (C3), 124.6 (C6), 126.6 (C7), 127.6 (C11), 132.5 (C8), 141.2 (C4), 153.5 (C2), 160.7 (C13, C15), 163.8 (COO), 184.1 (C10). Anal. calcd. for C~20~H~20~N~2~O~5~: C, 65.21; H, 5.47; N, 7.60%. Found: C, 65.18; H, 5.45; N, 7.63%.

*Ethyl 2-methyl-7--(4-bromobenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8h***. Beige solid, Yield: 42%; m.p. 145--147 ˚C; IR (KBr, cm^−1^): 2990, 1701, 1645, 1547, 1462, 1362, 1261, 1229, 1188, 1098, 754; ^1^H NMR (500 MHz CDCl~3~) δ 1.40 (t, *J* =  7.0 Hz, 3H, CH~3~), 2.65 (s, 3H, Me), 4.38 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.04 (d, *J* =  9.5 Hz, 1H, H3), 7.63 (s, 1H, H6), 7.65 (d, *J* =  8.0 Hz, 2H, H13, H15), 7.77 (d, *J* =  8.0 Hz, 2H, H12, H16), 8.54 (d, *J* =  9.0 Hz, 1H, H4). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.6 (CH~3~), 22.4 (Me), 60.6 (CH~2~), 105.4 (C5), 120.1 (C3), 124.4 (C6), 126.3 (C7), 127.3 (C14), 127.6 (C4), 131.2 (C12, C16), 131.8 (C13, C15), 132.6 (C8), 138.1 (C11), 153.7 (C2), 163.7 (COO), 183.3 (C10). Anal. calcd. for C~18~H~15~BrN~2~O~3~: C, 55.83; H, 3.90; N, 7.23%. Found: C, 55.85; H, 3.87; N, 7.26%.

*Ethyl 2--(4-chlorophenyl)-7--(3,4,5-trimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8i***. Beige solid, Yield: 41%; m.p. 230--232 ˚C; IR (KBr, cm^−1^): 2984, 1697, 1657, 1583, 1503, 1460, 1314, 1234, 1169, 1130, 808; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.90 (s, 6H, 2 × OMe), 3.97 (s, 3H, OMe), 4.42 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.20 (s, 2H, H12, H16), 7.47 (d, *J* =  8.5 Hz, 2H, H19, H21), 7.47 (d, *J* =  9.0 Hz, 1H, H4), 7.79 (s, 1H, H6), 8.01 (d, *J* =  8.5 Hz, 2H, H18, H22), 8.69 (d, *J* =  9.0 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 56.5 (2 × OMe), 60.6 (CH~2~), 61.2 (OMe), 105.6 (C5), 107.3 (C12, C16), 115.8 (C4), 124.4 (C6), 127.1 (C7), 128.4 (C3, C18, C22), 129.5 (C19, C21), 132.2 (C11), 133.6 (C17), 134.2 (C8), 136.9 (C20), 142.3 (C14), 151.1 (C2), 153.2 (C13, C15), 163.7 (COO), 183.6 (C10). Anal. calcd. for C~26~H~23~ClN~2~O~6~: C, 63.10; H, 4.68; N, 5.66%. Found: C, 63.15; H, 4.67; N, 5.69%.

*Ethyl 2--(4-chlorophenyl)-7--(3,5-dimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8j***. Beige solid, Yield: 41%; m.p. 193--195 ˚C; IR (KBr, cm^−1^): 2949, 1694, 1659, 1599, 1458, 1298, 1094, 810; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.85 (s, 6H, 2 × OMe), 4.40 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.71 (bs, 1H, H14), 7.05 (d, *J* =  2.0 Hz, 2H, H12, H16), 7.47 (d, *J* =  8.5 Hz, 2H, H19, H21), 7.59 (d, *J* =  9.5 Hz, 1H4), 7.81 (s, 1H, H6), 8.01 (d, *J* =  8.5 Hz, 2H, H18, H22), 8.70 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 55.8 (2 × OMe), 60.6 (CH~2~), 104.8 (C14), 105.7 (C5), 107.5 (C12, C16), 115.9 (C4), 125.0 (C6), 127.1 (C7), 128.4 (C18, C22), 128.5 (C3), 129.5 (C19, C21), 132.4 (C8), 133.7 (C17), 136.8 (C20), 141.1 (C11), 151.2 (C2), 160.9 (C13, C15), 163.7 (COO), 184.2 (C10). Anal.calcd. for C~25~H~21~ClN~2~O~5~: C, 64.59; H, 4.55; N, 6.03%. Found: C, 64.64; H, 4.50; N, 6.10%.

*Ethyl 2--(4-chlorophenyl)-7--(3,4-dimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8k***. Beige solid, Yield: 42%; m.p. 161--163 ˚C; IR (KBr, cm^−1^): 2982, 1696, 1649, 1595, 1462, 1269, 1234, 1090, 806; ^1^H NMR (500 MHz CDCl~3~) δ 1.43 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.97 (s, 3H, OMe), 3.99 (s, 3H, OMe), 4.41 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.95 (d, *J* =  8.0 Hz, 1H, H15), 7.46 (d, *J* =  8.5 Hz, 2H, H19, H21), 7.56 (m, 3H, H12, H16, H4), 7.76 (s, 1H, H6), 8.00 (d, *J* =  8.5 Hz, 2H, H18, H22), 8.68 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.8 (CH~3~), 56.3 (OMe), 56.4 (OMe), 60.7 (CH~2~), 105.4 (C5), 110.2 (C15), 112.0 (C12), 115.7 (C4), 124.2 (C6), 124.9 (C16), 127.4 (C7), 128.6 (C3, C18, C22), 129.5 (C19, C21), 131.9 (C11), 132.1 (C17), 133.8 (C8), 136.9 (C20), 151.1 (C2), 149.4 (C13), 153.4 (C14), 163.9 (COO), 183.5 (C10). Anal. calcd. for C~25~H~21~ClN~2~O~5~: C, 64.59; H, 4.55; N, 6.03%. Found: C, 64.60; H, 4.49; N, 6.07%.

*Ethyl 2--(4-chlorophenyl)-7--(4-bromobenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8l***. White solid; Yield: 45%; m.p. 163--165 ˚C; IR (KBr, cm^−1^) 3051, 2988, 1694, 1458, 1242, 1207, 1090, 808; ^1^H N,R (500 MHz CDCl~3~) δ 1.43 (t, *J* =  7.0 Hz, 3H, CH~3~), 4.41 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.47 (d, *J* =  8.5 Hz, 2H, H19, H21), 7.59 (d, *J* =  9.5 Hz, H4), 7.67 (d, *J* =  8.0 Hz, 2H, H12, H16), 7.76 (s, 1H, H6), 7.78 (d, *J* =  8.0 Hz, 2H, H13, H15), 7.96 (d, *J* =  8.5 Hz, 2H, H18, H22), 8.70 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 60.7 (CH~2~), 105.9 (C5), 116.1 (C4), 124.8 (C6), 126.9 (C14), 127.4 (C7), 128.4 (C18, C22), 128.5 (C3), 129.5 (C19, C21), 132.4 (C8), 133.5 (C17), 131.1 (C13, C15), 131.9 (C12, C16), 137.0 (C20), 138.0 (C11), 151.3 (C2), 163.6 (COO), 183.5 (C10). Anal. calcd. for C~23~H~16~BrClN~2~O~3~: C, 57.11; H, 3.33; N, 5.79%. Found: C, 57.10; H, 3.29; N, 5.85%.

*Ethyl 2--(4-bromophenyl)-7--(3,4,5-trimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8m***. Beige solid, Yield: 50%; m.p. 238--240 ˚C; IR (KBr, cm^−1^): 2984, 2930, 1697, 1657, 1586, 1503, 1458, 1314, 1234, 1169, 1128, 808, 752; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.90 (s, 6H, 2 × OMe), 3.97 (s, 3H, OMe), 4.42 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.20 (s, 2H, H12, H16), 7.58 (d, *J* =  9.0 Hz, H4), 7.63 (d, *J* =  8.5 Hz, 2H, H19, H21), 7.80 (s, 1H, H6), 7.94 (d, *J* =  8.5 Hz, 2H, H18, H22), 8.69 (d, *J* =  9.0 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 56.5 (2 × OMe), 60.6 (CH~2~), 61.2 (OMe), 105.6 (C5), 107.4 (C12, C16), 115.7 (C4), 124.4 (C6), 125.3 (C20), 127.1 (C7), 128.5 (C3), 128.7 (C18, C22), 132.5 (C19, C21), 132.2 (C11), 134.1 (C17), 134.2 (C8), 142.3 (C14), 151.2 (C2), 153.2 (C13, C15), 163.7 (COO), 183.6 (C10). Anal. calcd. for C~26~H~23~BrN~2~O~6~: C, 57.90; H, 4.30; N, 5.19%. Found: C, 57.95; H, 4.27; N, 5.24%.

*Ethyl 2--(4-bromophenyl)-7--(3,5-dimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8n***. Beige solid, Yield: 51%; m.p. 193--195 ˚C; IR (KBr, cm^−1^): 2982, 1695, 1659, 1591, 1458, 1298, 1155, 1096, 808; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.85 (s, 6H, 2 × OMe), 4.40 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.71 (t, *J* =  2.5 Hz, 1H, H14), 7.05 (d, *J* =  2.5 Hz, 2H, H12, H16), 7.58 (d, *J* =  9.5 Hz, H4), 7.63 (d, *J* =  8.5 Hz, 2H, H19, H21), 7.81 (s, 1H, H6), 7.94 (d, *J* =  8.5 Hz, 2H, H18, H22), 8.70 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 55.8 (2 × OMe), 60.6 (CH~2~), 104.8 (C14), 105.7 (C5), 107.5 (C12, C16), 115.9 (C4), 125.0 (C6), 125.2 (C20), 127.1 (C7), 128.4 (C3), 128.7 (C18, C22), 132.4 (C19, C21, C8), 134.1 (C17), 141.1 (C11), 151.2 (C2), 160.9 (C13, C15), 163.7 (COO), 184.2 (C10). Anal. calcd. for C~25~H~21~BrN~2~O~5~: C, 58.95; H, 4.16; N, 5.50%. Found: C, 58.94; H, 4.09; N, 5.55%.

*Ethyl 2--(4-bromophenyl)-7--(3,4-dimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8o***. Beige solid, Yield: 52%; m.p. 166--167 ˚C; IR (KBr, cm^−1^): 2975, 2929, 1719, 1680, 1592, 1458, 1269, 1236, 1147, 1087; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.97 (s, 3H, OMe), 3.99 (s, 3H, OMe), 4.41 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.95 (d, *J* =  7.5 Hz, 1H, H15), 7.57--7.62 (m, 5H, H12, H16, H4, H19, H21), 7.76 (s, 1H, H6), 7.93 (d, *J* =  8.0 Hz, 2H, H18, H22), 8.67 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 56.2 (OMe), 56.3 (OMe), 60.6 (CH~2~), 105.4 (C5), 110.1 (C15), 111.8 (C12), 115.5 (C4), 124.1 (C6), 124.8 (C16), 125.1 (C20), 127.3 (C7), 128.4 (C3), 128.7 (C18, C22), 131.7 (C11), 132.4 (C19, C21), 132.0 (C8), 134.2 (C17), 149.3 (C13), 151.1 (C2), 153.2 (C14), 163.8 (COO), 183.4 (C10). Anal. calcd. for C~25~H~21~BrN~2~O~5~: C, 58.95; H, 4.16; N, 5.50%. Found: C, 58.97; H, 4.10; N, 5.53%.

*Ethyl 2--(4-bromophenyl)-7--(4-bromobenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8p***. White solid, Yield: 45%; m.p. 171--173 ˚C; IR (KBr, cm^−1^): 3051, 2988, 1694, 1657, 1458, 1242, 1209, 1094, 1072, 806, 748; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 4.41 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.63 (d, *J* =  8.5 Hz, 2H, H19, H21), 7.59 (d, *J* =  9.5 Hz, H4), 7.67 (d, *J* =  8.0 Hz, 2H, H12, H16), 7.76 (s, 1H, H6), 7.77 (d, *J* =  8.0 Hz, 2H, H13, H15), 7.88 (d, *J* =  8.5 Hz, 2H, H18, H22), 8.70 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.6 (CH~3~), 60.7 (CH~2~), 105.9 (C5), 116.0 (C4), 124.8 (C6), 125.3 (C20), 126.9 (C14), 127.4 (C7), 128.5 (C3), 128.7 (C18, C22), 131.1 (C19, C21), 131.9 (C13, C15), 132.4 (C8), 132.5 (C12, C16), 133.9 (C17), 138.0 (C11), 151.4 (C2), 163.6 (COO), 183.5 (C10). Anal. calcd. for C~23~H~16~Br~2~N~2~O~3~: C, 52.30; H, 3.05; N, 5.30%. Found: C, 52.30; H, 3.00; N, 5.32%.

*Ethyl 2-(p-tolyl)-7--(3,4,5-trimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8q***. White solid, Yield: 40%; m.p. 198--200 ˚C; IR (KBr, cm^−1^): 3020, 2978, 2943, 1697, 1657, 1586, 1503, 1460, 1333, 1234, 1130, 1130, 806, 750; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 2.41 (s, 3H, Me), 3.89 (s, 6H, 2 × OMe), 3.97 (s, 3H, OMe), 4.41 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.20 (s, 2H, H12, H16), 7.29 (d, *J* =  8.5 Hz, 2H, H19, H21), 7.60 (d, *J* =  9.5 Hz, 1H4), 7.78 (s, 1H, H6), 7.94 (d, *J* =  8.5 Hz, 2H, H18, H22), 8.66 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 21.5 (Me), 56.5 (2 × OMe), 60.5 (CH~2~), 61.2 (OMe), 105.4 (C5), 107.3 (C12, C16), 116.3 (C4), 124.2 (C6), 127.0 (C18, C22), 127.1 (C7), 128.1 (C3), 129.9 (C19, C21), 132.2 (C11), 132.3 (C17), 134.3 (C8), 140.9 (C20), 142.1 (C14), 152.2 (C2), 153.1 (C13, C15), 163.8 (COO), 183.7 (C10). Anal. calcd. for C~27~H~26~N~2~O~6~: C, 68.34; H, 5.52; N, 5.90%. Found: C, 68.35; H, 5.47; N, 5.94%.

*Ethyl 2-(p-tolyl)-7--(3,5-dimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8r***. Beige solid, Yield: 40%; m.p. 142--144 ˚C; IR (KBr, cm^−1^): 2999, 2918, 1686, 1649, 1593, 1452, 1302, 1236, 1159, 1053, 804, 754; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 2.41 (s, 3H, Me), 3.84 (s, 6H, 2 × OMe), 4.40 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.97 (bs, 1H, H14), 7.05 (bs, 2H, H12, H16), 7.29 (d, *J* =  8.0 Hz, 2H, H19, H21), 7.60 (d, *J* =  9.5 Hz, H4), 7.79 (s, 1H, H6), 7.95 (d, *J* =  8.5 Hz, 2H, H18, H22), 8.65 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 21.5 (Me), 55.8 (2 × OMe), 60.5 (CH~2~), 104.7 (C14), 105.4 (C5), 107.4 (C12, C16), 116.4 (C4), 124.9 (C6), 127.0 (C7), 127.1 (C18, C22), 128.0 (C3), 129.9 (C19, C21), 132.3 (C8), 132.5 (C17), 140.8 (C20), 141.3 (C11), 152.3 (C2), 160.8 (C13, C15), 163.8 (COO), 184.2 (C10). Anal. calcd. for C~26~H~24~N~2~O~5~: C, 70.26; H, 5.44; N, 6.30%. Found: C, 70.29; H, 5.39; N, 6.33%.

*Ethyl 2-(p-tolyl)-7--(3,4-dimethoxybenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8s***. Beige solid, Yield: 40%; m.p. 150--151 ˚C; IR (KBr, cm^−1^): 3088, 2974, 2929, 1721, 1681, 1614, 1514, 1457, 1272, 1148, 1088; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.96 (s, 3H, OMe), 3.98 (s, 3H, OMe), 4.41 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.95 (d, *J* =  8.0 Hz, 1H, H15), 7.28 (d, *J* =  8.0 Hz, 2H, H19, H21), 7.59 (m, 3H, H12, H16, H4), 7.74 (s, 1H, H6), 7.94 (d, *J* =  8.0 Hz, 2H, H18, H22), 8.65 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 56.2 (OMe), 56.3 (OMe), 60.5 (CH~2~), 105.0 (C5), 110.0 (C15), 111.8 (C12), 116.1 (C4), 123.9 (C6), 124.7 (C16), 127.1 (C18, C22), 127.2 (C7), 128.0 (C3), 129.9 (C19, C21), 131.9 (C11), 132.1 (C17), 132.4 (C8), 140.7 (C20), 149.2 (C13), 152.1 (C2), 153.1 (C14), 164.0 (COO), 183.5 (C10). Anal. calcd. for C~26~H~24~N~2~O~5~: C, 70.26; H, 5.44; N, 6.30%. Found: C, 70.30; H, 5.40; N, 6.35%.

*Ethyl 2-(p-tolyl)-7--(4-bromobenzoyl)pyrrolo\[1,2-b\]pyridazine-5-carboxylate****8t***. Yellow solid, Yield: 40%; m.p. 160--162 ˚C; IR (KBr, cm^−1^): 3072, 2974, 1697, 1620, 1503, 1452, 1219, 1211, 1082, 816; ^1^H NMR (500 MHz CDCl~3~) δ 1.42 (t, *J* =  7.0 Hz, 3H, CH~3~), 2.42 (s, 3H, Me), 4.41 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.29 (d, *J* =  8.5 Hz, 2H, H19, H21), 7.62 (d, *J* =  9.5 Hz, H4), 7.67 (d, *J* =  7.5 Hz, 2H, H12, H16), 7.75 (s, 1H, H6), 7.76 (d, *J* =  8.0 Hz, 2H, H13, H15), 7.89 (d, *J* =  8.0 Hz, 2H, H18, H22), 8.67 (d, *J* =  9.5 Hz, 1H, H3). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.7 (CH~3~), 21.6 (Me), 60.6 (CH~2~), 105.7 (C5), 116.5 (C4), 124.6 (C6), 127.0 (C14), 127.1 (C18, C22), 127.2 (C7), 128.1 (C3), 130.0 (C19, C21), 132.2 (C17), 132.5 (C8), 131.1 (C13, C15), 131.9 (C12, C16), 138.0 (C11), 141.0 (C20), 152.4 (C2), 163.7 (COO), 183.6 (C10). Anal. calcd. for C~24~H~19~BrN~2~O~3~: C, 62.22; H, 4.13; N, 6.05%. Found: C, 62.25; H, 4.05; N, 6.08%.

*2--(2-Oxo-2--(3,4,5-trimethoxyphenyl)ethyl)phthalazin-2-ium bromide****10a***. Brown solid, Yield: 77%; m.p. 150--152 ˚C; IR (KBr, cm^−1^): 2976, 1670, 1584, 1339, 1125, 764. ^1^H NMR (500 MHz DMSO-d~6~) δ 3.80 (s, 3H, OMe), 3.91 (s, 6H, 2 × OMe), 6.87 (s, 2H, H11), 7.44 (s, 2H, H14, H18), 8.50 (t, *J* =  7.5 Hz, 1H, H6), 8.62 (t, *J* =  8.0 Hz, H5), 8.69 (d, *J* =  8.0 Hz, 1H, H4), 8.76 (d, *J* =  8.0 Hz, 1H, H7), 10.24 (s, 1H, H3), 10.77 (s, 1H, H8). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 56.4 (2 × OMe), 60.4 (OMe), 69.0 (C11), 106.3 (C14, C18), 127.3 (C10), 127.5 (C9), 128.6 (C13), 128.7 (C4), 130.8 (C7), 136.6 (C6), 139.9 (C5), 143.3 (C16), 153.1 (C15, C17), 153.5 (C8), 154.9 (C3), 189.6 (C12). Anal. calcd. for C~19~H~19~BrN~2~O~4~: C, 54.43; H, 4.57; N, 6.68%. Found: C, 54.47; H, 4.54; N, 6.71%.

*2--(2-Oxo-2--(3,5-dimethoxyphenyl)ethyl)phthalazin-2-ium bromide****10b***. Brown solid, Yield: 76%; m.p. 178--180 ˚C; IR (KBr, cm^−1^): 2976, 1703, 1589, 1319, 1011. ^1^H NMR (500 MHz DMSO-d~6~) δ 3.86 (s, 6H, 2 × Me), 6.79 (s, 2H, H11), 6.93 (t, *J* =  2.0 Hz, 1H, H16), 7.26 (d, *J* =  2.0 Hz, 2H, H14, H18), 8.51 (t, *J* =  8.0 Hz, 1H, H6), 8.61 (t, *J* =  8.0 Hz, H5), 8.67 (d, *J* =  8.0 Hz, 1H, H4), 8.75 (d, *J* =  8.0 Hz, 1H, H7), 10.21 (s, 1H, H3), 10.69 (s, 1H, H8). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 55.8 (2 × OMe), 69.1 (C11), 106.3 (C14, C18), 106.6 (C16), 127.3 (C10), 127.5 (C9), 128.6 (C4), 130.8 (C7), 135.3 (C13), 136.6 (C6), 139.9 (C5), 153.6 (C8), 154.9 (C3), 160.9 (C15, C17), 190.5 (C12). Anal. calcd. for C~18~H~17~BrN~2~O~3~: C, 55.54; H, 4.40; N, 7.20%. Found: C, 55.55; H, 4.37; N, 7.22%.

*2--(2-Oxo-2--(3,4-dimethoxyphenyl)ethyl)phthalazin-2-ium bromide****10c***. Brown solid, Yield: 74%; m.p. 224--226 ˚C; IR (KBr, cm^−1^): 3017, 2974, 1701, 1589, 1313, 1204, 1011. ^1^H NMR (500 MHz DMSO-d~6~) δ 3.86 (s, 3H, OMe), 3.92 (s, 3H, OMe), 6.74 (s, 2H, H11), 6.98 (d, *J* =  8.0 Hz, 1H, H17), 7.47 (overlapped signals, 2H, H14, H18), 8.47 (t, *J* =  8.0 Hz, 1H, H6), 8.60 (t, *J* =  8.0 Hz, H5), 8.68 (d, *J* =  8.0 Hz, 1H, H4), 8.76 (d, *J* =  8.0 Hz, 1H, H7), 10.25 (s, 1H, H3), 10.72 (s, 1H, H8). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 55.8 (OMe), 56.1 (OMe), 68.9 (C11), 110.5 (C14), 111.4 (C18), 123.8 (C17), 126.2 (C13), 127.5 (C9), 128.7 (C4), 130.9 (C7), 136.6 (C6), 139.9 (C5), 148.9 (C15), 153.5 (C8), 154.9 (C3), 154.5 (C16), 188.9 (C12). Anal. calcd. for C~18~H~17~BrN~2~O~3~: C, 55.54; H, 4.40; N, 7.20%. Found: C, 55.55; H, 4.37; N, 7.22%.

*2--(2-Oxo-2--(4-bromophenyl)ethyl)phthalazin-2-ium bromide****10d***. White solid, Yield: 76%; m.p. 222--224 ˚C; IR (KBr, cm^−1^): 3013, 1684, 1613, 1580, 1352. ^1^H NMR (500 MHz DMSO-d~6~) δ 6.83 (s, 2H, H~11~) 7.89 (d, *J* = 8.5 Hz, 2H, H15, H17), 8.08 (d, *J* =  8.5 Hz, 2H, H14, H18), 8.48 (t, *J* =  8.0 Hz, 1H, H6), 8.61 (t, *J* =  8.0 Hz, H5), 8.68 (d, *J* =  8.0 Hz, 1H, H4), 8.75 (d, *J* =  8.0 Hz, 1H, H7), 10.23 (s, 1H, H3), 10.76 (s, 1H, H8). ^13 ^C NMR (125 MHz DMSO-d~6~) *δ* 68.8 (C11), 127.3 (C10), 127.5 (C9), 128.6 (C4), 129.2 (C16), 130.5 (C14, C18), 130.8 (C7), 132.3 (C15, C17), 132.5 (C13), 136.6 (C6), 139.9 (C5), 153.5 (C8), 154.9 (C3), 190.1 (C12). Anal. calcd. for C~16~H~12~Br~2~N~2~O: C, 47.09; H, 2.96; N, 6.86%. Found: C, 48.11; H, 2.94; N, 6.88%.

*Ethyl 3--(3,4,5-trimethoxybenzoyl)pyrrolo\[2,1-a\]phthalazine-1-carboxylate****11a***. White solid, Yield: 40%; m.p. 235--237 ˚C; IR (KBr, cm^−1^): 3041, 2933, 2835, 1711, 1650, 1583, 1261, 1172, 1130, 1042, 785; ^1^H NMR (500 MHz CDCl~3~) δ 1.41 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.90 (s, 6H, 2 × OMe), 3.90 (s, 3H, OMe), 4.41 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.24 (s, 2H, H16, H20), 7.73 (s, 1H, H2), 7.76 (d, *J* =  7.5 Hz, 1H, H7), 7.90 (overlapped signals, 2H, H8, H6), 8.75 (s, 1H, H5), 9.84 (d, *J* =  8.0 Hz, 1H, H9). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.6 (CH~3~), 56.5 (2 × OMe), 60.9 (CH~2~), 61.2 (OMe), 107.6 (C16, C20), 108.3 (C1), 122.3 (C11), 124.2 (C2), 127.0; 127.1 (C12, C3), 127.6 (C9), 127.7 (C6), 129.8 (C7), 130.2 (C13), 133.1 (C8), 134.1 (C15), 142.3 (C18), 146.5 (C5), 153.1 (C17, C19), 164.4 (COO), 183.8 (C14). Anal. calcd. for C~24~H~22~N~2~O~6~: C, 66.35; H, 5.10; N, 6.45%. Found: C, 66.58; H, 5.05; N, 6.48%.

*Ethyl 3--(3,5-dimethoxybenzoyl)pyrrolo\[2,1-a\]phthalazine-1-carboxylate****11b***. White solid, Yield: 41%; m.p. 220--222 ˚C; IR (KBr, cm^−1^): 3040, 2969, 2835, 1707, 1649, 1595, 1458, 1383, 1173, 1096, 756; ^1^H NMR (500 MHz CDCl~3~) δ 1.41 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.85 (s, 6H, 2 × OMe), 4.41 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.70 (bs, 1H, H18), 7.08 (d, *J* =  2.0 Hz, 2H, H16, H20), 7.74 (overlapped signals, 2H, H2, H7), 7.90 (overlapped signals, 2H, H8, H6), 8.76 (s, 1H, H5), 9.83 (d, *J* =  8.5 Hz, 1H, H9). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.6 (CH~3~), 55.8 (2 × OMe), 60.9 (CH~2~), 105.0 (C18), 107.8 (C16, C20), 108.4 (C1), 122.3 (C11), 124.8 (C2), 127.0; 127.1 (C12, C3), 127.6 (C9), 127.7 (C6), 129.8 (C7), 130.4 (C13), 133.0 (C8), 141.1 (C15), 146.6 (C5), 160.7 (C17, C19), 164.4 (COO), 184.3 (C14). Anal. calcd. for C~23~H~20~N~2~O~5~: C, 68.31; H, 4.98; N, 6.93%. Found: C, 68.34; H, 4.95; N, 6.96%.

*Ethyl 3--(3,4-dimethoxybenzoyl)pyrrolo\[2,1-a\]phthalazine-1-carboxylate****11c***. White solid, Yield: 41%; m.p. 226--228 ˚C; IR (KBr, cm^−1^): 3101, 2959, 2932, 1713, 1645, 1466, 1412, 1263, 1177, 1024, 764; ^1^H NMR (500 MHz CDCl~3~) δ 1.41 (t, *J* =  7.0 Hz, 3H, CH~3~), 3.96 (s, 3H, OMe), 3.97 (s, 3H, OMe), 4.40 (q, *J* =  7.0 Hz, 2H, CH~2~), 6.94 (d, *J* =  8.0 Hz, 1H, H19), 7.58 (overlapped signals, 2H, H16, H20), 7.68 (s, 1H, H2), 7.73 (t, *J* =  7.5 Hz, 1H, H7), 7.88 (overlapped signals, 2H, H8, H6), 8.71 (s, 1H, H5), 9.82 (d, *J* =  8.0 Hz, 1H, H9). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.6 (CH~3~), 56.22 (OMe), 56.23 (OMe), 60.8 (CH~2~), 108.1 (C1), 110.1 (C16), 112.1 (C19), 122.2 (C11), 123.5 (C2), 125.1 (C20), 127.1 (C3), 127.3 (C12), 127.5 (C9), 127.7 (C6), 129.7 (C7), 129.9 (C13), 131.7 (C15), 133.0 (C8), 146.4 (C5), 149.2 (C17), 153.3 (C18), 164.5 (COO), 183.8 (C14). Anal. calcd. for C~23~H~20~N~2~O~5~: C, 68.31; H, 4.98; N, 6.93%. Found: C, 68.32; H, 4.97; N, 6.94%.

*Ethyl 3--(4-bromobenzoyl)pyrrolo\[2,1-a\]phthalazine-1-carboxylate****11d***[@CIT0035]. White solid, Yield: 51%; m.p. 180--182 ˚C; IR (KBr, cm^−1^): 2980, 1722, 1653, 1587, 1464, 1379, 1242; ^1^H NMR (500 MHz CDCl~3~) δ 1.38 (t, *J* =  7.0 Hz, 3H, CH~3~), 4.37 (q, *J* =  7.0 Hz, 2H, CH~2~), 7.62 (d, *J* =  8.5 Hz, 2H, H17, H19), 7.65 (s, 1H, H2), 7.74 (t, *J* =  8.0 Hz, 1H, H7), 7.78 (d, *J* =  8.5 Hz, 2H, H16, H20), 7.87 (overlapped signals, 2H, H8, H6), 8.73 (s, 1H, H5), 9.80 (d, *J* =  8.5 Hz, 1H, H9). ^13 ^C NMR (125 MHz CDCl~3~) *δ* 14.5 (CH~3~), 60.9 (CH~2~), 108.5 (C1), 122.3 (C11), 124.7 (C2), 126.7 (C12); 126.8 (C18), 127.5 (C3), 127.6 (C9), 127.7 (C6), 129.9 (C7), 130.5 (C13), 131.3 (C16, C20), 131.7 (C17, C19), 133.1 (C8), 137.9 (C15), 146.6 (C5), 164.2 (COO), 183.5 (C14). Anal. calcd. for C~21~H~15~BrN~2~O~3~: C, 59.59; H, 3.57; N, 6.62%. Found: C, 59.62; H, 3.55; N, 6.64%.

Molecular modelling {#s0006}
-------------------

Flexible docking experiments were carried out in Autodock Vina[@CIT0040], using a 18x22x22 Å3 grid box centered on the colchicine binding site of the α,β-tubulin heterodimer crystal structure (PDB: 1SA0)[@CIT0041]. The 3 D structures of the compounds were constructed in Avogadro v1.2.0[@CIT0042] and were subjected to 10,000 steepest descent steps of energy minimisation in the MMFF94 force field. One hundred poses were generated for each ligand, and the best-ranked models were chosen for further visual inspection in order to assess the consistency of the generated docking solutions relative to the docking poses of known inhibitor colchicine. Molecular graphics and visual analyses were performed in The PyMOL Molecular Graphics System, Version 1.8.2. (Schrödinger, LLC). Log*p* values were calculated using the ChemAxon/Chemicalize server ([www.chemicalize.com](http://www.chemicalize.com)).

Cell proliferation assay {#s0007}
------------------------

The compounds were tested against a panel of 60 human cancer cell lines at the National Cancer Institute, Rockville, MD. The cytotoxicity experiments were realised using a 48 h exposure protocol using sulphorhodamine B assay[@CIT0043].

Results and discussion {#s0008}
======================

Chemistry {#s0009}
---------

The chosen method for the assembly of pyrrolo\[1,2-*b*\]pyridazine moieties relied on 1,3-dipolar cycloaddition of different pyridazinium ylides to ethyl propiolate.

First, pyridazines **1**--**5** ([Scheme 1](#SCH0001){ref-type="scheme"}) were used for the synthesis of their monoquaternary salts with 2-bromoacetophenones **6a--d**. While compound **6d** is commercially available, compounds **6a--c** were synthesised using reported procedures[@CIT0046]. The quaternisation reactions were carried out at room temperature (r.t.) in a minimal amount of acetone, leading to the formation of salts **7a--t** ([Scheme 1](#SCH0001){ref-type="scheme"}).

![Synthesis of pyridazin-1-ium quaternary salts **7a--t.**](IENZ_A_1550085_SCH0001_B){#SCH0001}

As shown in [Scheme 2](#SCH0002){ref-type="scheme"}, ethyl propiolate was reacted with the corresponding pyridazinium ylides **7′a--t** (*in situ* generated in basic medium from salts **7a--t**) to give the intermediate dihydropyrrolo\[1,2-*b*\]pyridazines **8′a--t**, which in turn underwent oxidative dehydrogenation under atmospheric conditions, yielding the final compounds **8a**--**t** in moderate yields (40--52%) ([Scheme 2](#SCH0002){ref-type="scheme"}).

![Synthesis of pyrrolo\[1,2-*b*\]pyridazines **8a--t.**](IENZ_A_1550085_SCH0002_B){#SCH0002}

For the synthesis of compounds **11**, in a similar manner, phthalazine was first reacted with 2-bromoacetophenones **6a--d**, to give monoquaternary salts **10a**--**d** ([Scheme 3](#SCH0003){ref-type="scheme"}). Phthalazinium salts **10a--d** furnished pyrrolo\[2,1-*a*\]phthalazines **11a--d** when treated with triethylamine and ethyl propiolate in acetone at room temperature ([Scheme 3](#SCH0003){ref-type="scheme"}).

![Synthesis of pyrrolo\[2,1-*a*\]phthalazines **11a--d** from phthalazine via quaternary phthalazinum salts **10a--d.**](IENZ_A_1550085_SCH0003_B){#SCH0003}

Biological activity {#s0010}
-------------------

Fourteen of the synthesised compounds (**8a, b, d, e, f, h, i, j, k, n, q,** and **11a--c**) were selected by the National Cancer Institute (NCI) for screening against a panel of 60 human tumour cell lines at a single dose of 10 μM[@CIT0043], the representative results for the active compounds being summarised in [Table 1](#t0001){ref-type="table"}.

###### 

Results of the *in vitro* growth inhibition (GI %) caused by compounds **8a, b, d, e, f, h** and **11a-c** against human cancer cell lines in the single-dose assay^a^.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell type          Compound          8a                8b                8d                8e                8f                8h   11a               11b               11c
  ------------------ ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ---- ----------------- ----------------- -----
  Leukemia           CCRF-CEM          89                76                23                83                86                4    30                77                11

  K-562              89                78                79                **90**            **90**            6                 77   **94**            11                

  SR                 82                68                72                77                82                18                77   **95**            27                

  HL-60(TB)          **100^b^ (33)**   **100^b^ (22)**   47                **100^b^ (24)**   **100^b^ (17)**   11                71   **100^b^ (8)**    18                

  MOLT-4             81                67                31                82                70                23                38   71                31                

  RPMI-8226          79                71                51                82                88                22                18   67                21                

  Non-small\         A549/ATCC         76                65                27                73                73                23   45                82                20
  Cell lung cancer                                                                                                                                                        

  HOP-62             68                69                23                49                52                21                10   57                10                

  NCI-H460           **90**            85                0                 **90**            89                0                 49   **93**            0                 

  NCI-H522           65                75                84                **96**            **100^b^ (11)**   34                60   **97**            16                

  Colon cancer       COLO205           **100^b^ (25)**   **100^b^ (13)**   29                **100^b^ (39)**   **100^b^ (11)**   1    40                81                0

  HCT-116            88                86                54                85                75                22                49   **96**            19                

  HCT-15             76                78                30                75                68                8                 41   70                23                

  HT-29              **96**            **93**            40                **92**            **96**            27                70   **98**            0                 

  SW-620             66                81                60                73                82                6                 64   **92**            1                 

  KM12               79                72                48                72                70                8                 60   84                4                 

  CNS cancer         SF-295            86                72                26                59                76                1    27                **91**            13

  SF-539             **100^b^ (12)**   80                22                85                **96**            6                 13   89                4                 

  SNB-75             66                76                31                52                82                21                21   **100^b^ (10)**   14                

  U251               85                75                35                81                77                28                19   **100^b^ (13)**   14                

  Melanoma           LOX IMVI          57                60                9                 69                51                11   34                **90**            4

  M14                **96**            **100^b^ (16)**   45                79                89                0                 50   84                6                 

  MDA-MB-435         **100^b^ (57)**   **99**            88                **97**            **100^b^ (16)**   0                 93   **96**            1                 

  UACC-62            70                74                39                41                53                7                 30   58                1                 

  SK-MEL-2           42                79                55                72                84                19                22   85                3                 

  SK-MEL-5           74                74                37                **97**            69                10                66   81                34                

  Ovarian cancer     OVCAR-3           **100^b^ (15)**   **99**            22                87                **99**            0    53                **100^b^ (13)**   2

  NCI/ADR-RES        **97**            **93**            50                79                81                7                 36   81                12                

  SK-OV-3            73                80                27                76                **94**            25                17   62                7                 

  OVCAR-8            70                62                24                75                70                10                22   66                12                

  OVCAR-4            38                38                                  48                43                19                16   **100^b^ (18)**   0                 

  Renal cancer       A498              **100^b^ (5)**    **100^b^ (3)**    15                77                **100^b^ (2)**    7    26                84                18

  ACHN               48                47                                  51                40                1                 21   **98**            9                 

  RXF393             **100^b^ (4)**    64                25                66                86                21                12   71                10                

  TK-10              46                36                                  22                35                20                3    **100^b^ (9)**    15                

  Breast cancer      MCF7              80                75                51                78                79                12   70                84                14

  MDA-MB-468         **100^b^ (12)**   73                22                63                70                8                 1    57                5                 

  Prostate cancer    PC-3              78                64                33                69                75                24   45                68                24

  DU-145             76                63                6                 79                78                16                6    54                2                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The most active compounds are highlighted in bold.

Data obtained from NCI's *in vitro* 60 cell one dose screening at 10^−5^M concentration.

Cytotoxic effect; lethality percent is represented in brackets.

Pyrrolo\[2,1-*b*\]pyridazines **8a, 8b, 8e, 8f,** and pyrrolo\[2,1-*a*\]phthalazine **11b** showed a very good growth inhibition effect on almost all 60 cell lines, the best results being registered on leukemia HL-60 (TB) cell, colon cancer COLO205 cell, melanoma MDA-MB-435 cell, ovarian cancer cell OVCAR-3, and renal cancer A498 cell. Compound **8a** also showed a moderate cytotoxic effect, notably on melanoma MDA-MB-435 cells (57% cytotoxic). Mild to moderate cytotoxic effects were also observed for compounds **8b**, **8e**, **8f,** and **11b** against several cell types. Interestingly, the substitution of pyrrolo\[2,1-*b*\]pyridazine heterocycle at position 2 with a 4-substituted phenyl group resulted in the loss of the activity, compounds **8i--j**, **8k**, **8n,** and **8q** showing almost no inhibition effect against the 60 cell tested lines (data not shown). In contrast, 2-methylpyrrolo\[2,1-*b*\]pyridazines **8e--f** showed similar activity to unsubstituted compounds **8a--b**. Another interesting aspect is that substitution of the 3,4,5-trimethoxyphenyl ring of with a 3,5-dimethoxyphenyl one, did not diminish the inhibitory activity. In fact, pyrrolo\[2,1-*a*\]phthalazine compound **11b** showed better growth inhibitory properties when compared with **11a**. Substitution of the 3,4,5-trimethoxyphenyl ring with 3,4-dimethoxyphenyl or 4-bromophenyl also caused a reduction in biological activity, with the exception of compound **8d**, which maintained moderate GI% values on most tested cell lines, although lower than 3,4,5-trimethoxyphenyl-substituted analogues **8a--b**.

The most active compounds **8a, 8b, 8e, 8f,** and **11b** were selected for the second stage five dose-response studies[@CIT0042] selected results being presented in [Table 2](#t0002){ref-type="table"}.

###### 

Results of the 5-dose *in vitro* human cancer cell growth inhibition^a^ for compounds **8a--b, e--f** and **11b** and compared with standard drug Doxorubicin.

  -----------------------------------------------------------------------------------------------
  Cell type          Compound →   8a         8b         8e         8f     11b    Doxorubicin^c^
  ------------------ ------------ ---------- ---------- ---------- ------ ------ ----------------
  Leukemia           CCRF-CEM     261        2510       212        348    n.d.   79

  HL-60(TB)          228          1380       160        248        820    126    

  K-562              **90.6**     538        n.d.       n.d.       n.d.   200    

  MOLT-4             443          2630       396        527        n.d.   32     

  RPMI-8226          246          1820       n.d.       n.d.       n.d.   79     

  SR                 **46.1**     573        **48.1**   **75.9**   442    25     

  Non-small\         A549/ATCC    487        11100      223        767    n.d.   63
  Cell Lung cancer                                                               

  HOP-62             363          10200      398        691        n.d.   63     

  NCI-H460           312          2580       133        365        494    16     

  NCI-H522           343          346        171        303        236    32     

  Colon cancer       COLO205      193        797        n.d.       n.d.   n.d.   200

  HCT-116            276          n.d.       164        331        455    79     

  HCT-15             171          587        **84.4**   280        484    6310   

  HT-29              208          403        133        401        384    126    

  KM12               216          n.d.       **57.7**   254        351    251    

  SW-620             155          518        **68.7**   280        483    100    

  CNS cancer         SF-268       733        26500      550        676    1590   100

  SF-295             180          2100       **65.7**   311        483    100    

  SF-539             276          1850       130        349        1060   126    

  SNB-19             769          4260       420        752        1570   40     

  SNB-75             211          399        n.d.       384        471    63     

  U251               402          2000       331        549        730    40     

  Melanoma           MALME-3M     247        \>100000   n.d.       n.d.   1070   126

  M14                176          394        136        251        485    159    

  MDA-MB-435         **31.4**     221        **25.6**   **45.6**   188    251    

  SK-MEL-2           385          738        495        494        n.d.   159    

  SK-MEL-5           269          508        **58.5**   276        623    79     

  UACC-62            176          523        **61.5**   477        692    159    

  Ovarian cancer     OVCAR-3      145        402        **64.9**   289    341    398

  NCI/ADR-RES        200          463        123        308        476    7943   

  SK-OV-3            426          4900       546        878        n.d.   200    

  Renal cancer       786-0        395        11400      335        523    n.d.   126

  A498               **46.6**     n.d.       **76.2**   388        n.d.   100    

  CAKI-1             301          2976       n.d.       n.d.       n.d.   1000   

  RXF 393            185          1640       116        239        1070   100    

  Prostate cancer    PC-3         166        7450       **93.9**   317    839    316

  DU-145             333          3960       391        906        n.d.   100    

  Breast cancer      MCF7         **94.6**   1310       **48.1**   313    410    40

  HS 578T            236          1990       190        284        1840   316    

  BT-549             437          1220       878        1990       1180   251    

  T-47D              n.d.^c^      17200      \>100000   501        n.d.   63     

  MDA-MB-468         281          1110       **66.8**   297        403    50     
  -----------------------------------------------------------------------------------------------

The most active compounds are highlighted in bold.

Data obtained from NCI's *in vitro* 60 cell 5-dose screening[@CIT0043].

GI~50~ -- the molar concentration of tested compound causing 50% growth inhibition of tumor cells. Determined at five concentration levels (100, 10, 1.0, 0.1 and 0.01 μM).

GI~50~ data for Doxorubicin tested at a highest concentration of 100 μM were obtained from NCI database: <https://dtp.cancer.gov/dtpstandard/dwindex/index.jsp>.

n.d.: Not determined.

All five tested compounds confirmed the preliminary results by displaying good antiproliferative properties. The best candidate, 2-methyl-pyrrolo\[2,1-b\]pyridazine **8e** exhibited GI~50~ values \<100 nM in thirteen cell lines, notably on melanoma MDA-MB-435 cell (GI~50~ = 25.6 nM), leukemia SR cell (GI~50~ = 48.1 nM) and breast cancer MCF7 cell (GI~50~ = 48.1 nM). Compound **8e** showed better GI~50~ values against melanoma MDA-MB-435, SK-MEL-5, and UACC-62 and colon cancer HCT-15, KM12 and SW-620 cell than Doxorubicin (NSC: 123127 code), the NCI standard drug for this type of analysis.

Interestingly, even if it exhibits an overall inhibitory activity lower than the 2-methyl substituted compound **8e**, compound **8a** shows an excellent inhibitory activity on melanoma MDA-MB-435 cell (GI~50~ = 31.4 nM), leukemia SR cell (GI~50~ = 46.1 nM) and renal cancer A498 (GI~50~ = 46.6 nM). Also, compound **8f** displayed very good activity against melanoma MDA-MB-435 cell (GI~50~ = 45.6 nM).

Notably, compound **8e** showed a very good cytostatic activity on melanoma MDA-MB-435 cell with a total growth inhibition level of effect (TGI) of 76.3 nM and leukemia HL-60(TB) (TGI = 588 nM), whereas compounds **8a** and **8f** showed the best cytostatic activity on melanoma MDA-MB-435 cell with a TGI of 117 nM and 420 nM, respectively. Significant cytotoxic activity was exhibited only by compound **8a** on MDA-MB-435 melanoma cell with a lethal concentration (LC~50~) value of 438 nM.

Although pyrrolo\[2,1-a\]phthalazine **11b** displayed the best mean growth inhibitory effect in preliminary single dose evaluation ([Table 1](#t0001){ref-type="table"}), it did not exhibit GI~50~ values under the 100 nm threshold, as was the case for the more simple pyrrolo\[1,2-b\]pyridazines. Therefore, the introduction of a bulkier heterocycle, such as pyrrolo\[2,1-a\]phthalazine, in place of the 3′-hydroxy-4′-methoxyphenyl ring of phenstatin is less favourable in terms of antiproliferative activity than pyrrolo\[1,2-b\]pyridazine.

Molecular modelling {#s0011}
-------------------

Because both computational and biological models of 3,4,5-trimethoxyphenyl-containing phenstatin analogues supported the hypothesis that the antiproliferative effects of these compounds are induced by inhibiting tubulin polymerisation[@CIT0005]^,^[@CIT0007]^,^[@CIT0033]^,^[@CIT0047]^,^[@CIT0048], docking experiments were performed on the colchicine binding site of the α,β-tubulin heterodimer (PDB:1SA0), in order to evaluate the shape and electrostatic complementarity between ligands and the α,β-tubulin heterodimer interface, which could account for the observed antiproliferative effects.

Compounds **8a** and **8b** displayed similar docking conformations grouped into two distinct clusters, both having the trimethoxyphenyl subunit overlapping with the one in the co-crystallised DAMA-colchicine ligand ([Figure 2(a)](#F0002){ref-type="fig"}), and interacting with the protein through hydrogen bonding with βCys241. The ligands are further stabilised in the binding pocket through hydrophobic interactions with βLeu242, βLeu248, βAla250, βLeu252, βLeu255, and βVal238. The diazine moiety either extended on top of the binding pocket, with the ester functional group orienting towards the dimer interface ([Figure 2(b,c)](#F0002){ref-type="fig"}), or was flipped at about 180°, to have the ester group roughly overlapping with the third colchicine ring in the crystal structure. Interestingly, the 4-bromo-substituted compound **8d**, which displayed a less pronounced biological activity than **8a** and **8b**, adopted a conformation in which the *p*-bromo substituted phenyl was accommodated more deeply in the colchicine binding pocket, resulting in a shift in the position of the central heterocyclic moiety towards the center of the colchicine binding site, which led to the disruption of the hydrogen bond with βCys241 ([Figure 2(d)](#F0002){ref-type="fig"}).

![Structure and docking of diazines in the tubulin binding site: (a) DAMA-colchicine, (b) **8a**, (c) **8b**, (d) **8d**, (e) **8e**, (f) **8f**; the α,β-tubulin heterodimer is represented as ribbons; amino acids in the binding site are represented as sticks.](IENZ_A_1550085_F0002_C){#F0002}

Overall, the docking experiments suggest that the removal of the 4-methoxy group does not influence the accommodation of the ligand in the binding pocket, in agreement with the biological data, while the introduction of a bromine atom as substituent can induce a different binding conformation which leads to the disruption of the hydrogen bond between the ligand and βCys241, which could account for the reduced antiproliferative activity of compound **8d**.

The 2-methyl-substituted analogues of **8a** and **8b** (**8e** and **8f**) were accommodated in a similar fashion to that of parent compounds ([Figure 3(e,f)](#F0003){ref-type="fig"}), suggesting that the introduction of a methyl substituent does not influence the binding preferences of the compounds in the colchicine binding site, in agreement with the biological data in terms of antiproliferative activity. Compound **8h**, which displayed a marked reduction in biological activity when compared to parent compound **8d**, did not form the two expected well-defined clusters of conformations, but rather had a broad range of unrelated docking poses, the most energetically favourable being similar to the second cluster of compound **8d**.

![Structure and docking of diazines in the tubulin binding site: (a) **8i**, (b) **8j**, (c) **8k**, (d) **8n**; the α,β-tubulin heterodimer is represented as ribbons; amino acids in the binding site are represented as sticks.](IENZ_A_1550085_F0003_C){#F0003}

Interestingly, 2-(*p-*halogeno-phenyl)-substituted compounds **8i, 8j, 8k,** and **8n**, which showed a marked decrease in growth inhibition activity when compared to unsubstituted analogues, were compatible with the colchicine binding site, and were accommodated in a similar fashion to their unsubstituted or 2-methyl-substituted analogues with biological activity to the α,β-tubulin heterodimer ([Figures 2](#F0002){ref-type="fig"} and [3](#F0003){ref-type="fig"}). A closer inspection of the basic physicochemical properties of these four compounds reveals, however, a violation of Lipinski's rule of five in terms of log*p* values[@CIT0049] ([Table 3](#t0003){ref-type="table"}), which could account for the loss in antiproliferative efficacy in spite of apparent activity at the colchicine binding site[@CIT0050].

###### 

Theoretical log*p* values of biologically tested compounds.

  Compound   log*p*   Compound   log*p*   Compound   log*p*
  ---------- -------- ---------- -------- ---------- --------
  **8a**     2.77     **8h**     4.14     **8q**     5.32
  **8b**     2.93     **8i**     5.41     **11a**    3.76
  **8d**     4.01     **8j**     5.56     **11b**    3.92
  **8e**     2.90     **8k**     5.56     **11c**    3.92
  **8f**     3.06     **8n**     5.73                 

Values were calculated using the ChemAxon/Chemicalize server ([www.chemicalize.com](http://www.chemicalize.com)).

Docking of pyrrolo\[2,1-a\]phthalazines **11a--c** revealed a single cluster of conformations for each compound, similar to the second cluster obtained for pyrrolo\[1,2-b\]pyridazines **8a**, **8b**, **8e,** and **8f**, in which the heterocyclic subunit is oriented as to have the ester group roughly overlapping with the third colchicine ring in the crystal structure ([Figure 4](#F0004){ref-type="fig"}). The methoxyphenyl subunit is stabilised by a hydrogen bond interaction with βCys241, similar to the case of pyrrolo\[1,2-b\]pyridazine analogues. Notably, compound **11b** adopts a conformation slightly deeper in the hydrophobic pocket, which induces a rotation of the heterocyclic core and facilitates a hydrophobic interaction with βLeu248, which is unique among the three docked pyrrolo\[2,1-a\]phthalazines. A tighter hydrophobic interaction between **11b** and the protein could account for the pronounced antiproliferative activity exerted by **11b** among the three tested pyrrolo\[2,1-a\]phthalazines.

![Structure and docking of diazines in the tubulin binding site: (a) **11a**, (b) **11b**, (c) **11c**; the α,β-tubulin heterodimer is represented as ribbons; amino acids in the binding site are represented as sticks.](IENZ_A_1550085_F0004_C){#F0004}

However, for all compounds, complementary tubulin polymerisation assays are needed in order to confirm the proposed molecular mechanism.

Conclusion {#s0012}
==========

In summary, five of the newly synthesised pyrrolo\[1,2-*b*\]pyridazine and pyrrolo\[2,1-*a*\]phthalazine phenstatin analogues showed *in vitro* antiproliferative activity, the most potent being compounds **8f** with GI~50~ values \<100 nM on thirteen cell lines including colon, ovarian, renal, prostate, brain and breast cancer, melanoma and leukemia. Notably, compound **8a** showed a very good antiproliferative effect on melanoma MDA-MB-435 cell, renal cancer A498, and leukemia SR cell. The substitution of position 2 of pyrrolo\[1,2-*b*\]pyridazine with a methyl group generally appears to increase the antiproliferative potency of the compounds, while the introduction of a more bulkier substituent is completely detrimental for the growth inhibitory properties, despite the fact that docking studies showed a good compatibility with the colchicine binding site of tubulin. The lack of proliferative activity in the case of the bulkier 2--(4-X-phenyl)-pyrrolo\[1,2-*b*\]pyridazines could be explained by the suboptimal lipophilicity and solubility of these compounds. However, further assaying in terms of tubulin polymerisation is needed in order to confirm the proposed antiproliferative mechanism of action of the newly synthetised compounds. Compound **8f** could serve as a useful lead compound for further structural optimisation in the development of new anticancer agents.
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